Начало・Списък с акции・REGENXBIO Inc

REGENXBIO Inc

Затворен

СекторЗдравеопазване

10.3 4.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.23

Максимум

Ключови измерители
By Trading Economics
Приходи	-23M -90M
Продажби	-24M 6.4M
EPS	-1.72
Марж на печалбата	-1,408.588
Служители	371
EBITDA	-14M -77M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+160.78% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	101M 622M
Предишно отваряне	6.15
Предишно затваряне	10.3

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

REGENXBIO Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2026 г., 19:36 ч. UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30.07.2026 г., 19:29 ч. UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29.07.2026 г., 19:56 ч. UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28.07.2026 г., 18:16 ч. UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27.07.2026 г., 19:36 ч. UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24.07.2026 г., 20:07 ч. UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22.07.2026 г., 18:26 ч. UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21.07.2026 г., 19:31 ч. UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20.07.2026 г., 19:31 ч. UTC

Event

News

Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Сравнение с други в отрасъла

Ценова промяна

REGENXBIO Inc Прогноза

Ценова цел

By TipRanks

160.78% нагоре

12-месечна прогноза

Среден 25.27 USD 160.78%

Висок 45 USD

Нисък 10 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за REGENXBIO Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на REGENXBIO Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.